Treatment of Atopic Dermatitis With Different Orders of Application of Locoid Lotion and Hylatopic Plus Cream

Atopic Dermatitis Clinical Trial

Official title:

Assessment of Application Order When Utilizing Locoid Lotion and Hylatopic Plus Cream in the Treatment of Atopic Dermatitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02153762
• Other study ID #: GCO 12-1932
• Status: Completed
• Phase: N/A
• First received: May 27, 2014
• Last updated: April 11, 2017
• Start date: April 2013
• Est. completion date: January 2014

Study information

• Verified date: April 2017
• Source: Icahn School of Medicine at Mount Sinai
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability, as well as effectiveness, with regards to the order of application for Locoid Lipocream and Hylatopic Plus cream in patients with atopic dermatitis (AD), which is a type of skin rash.Topical skin barrier repair therapies (BRT) that are plain moisturizing creams/lotions with added lipids (fats/oils), such as Hylatopic Plus cream, have emerged as an effective addition to the the treatment of atopic dermatitis. BRTs are often used along with topical steroids (medicated creams), such as Locoid lotion, on skin with AD, and as a monotherapy (single treatment) on both non-diseased and diseased skin. Since BRTs help to restore components of skin that are absent in skin with AD, it is believed that long-term BRT use may reduce further development of further AD. This is an open-label, single site study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 41
• Est. completion date: January 2014
• Est. primary completion date: January 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Months and older

Eligibility

Inclusion Criteria:

• subjects of at least 3 months of age.

• clinical diagnosis of stable mild to moderate AD using the Hanifin and Rajka criteria for diagnosing AD

• AD lesions of similar size and severity of bilateral anatomic location

• a SPGA score of 2 or 3 and at least 10% BSA involvement at baseline

• in good health, without evidence of disease process(es) that would present patient safety concerns or confounding factors for assessment of study objectives

• able and willing to understand and sign an informed consent (or if applicable parent or legal guardian sign an informed consent),

• able and willing to agree to requirements and restrictions of the study

• Subjects who are willing to discontinue all systemic corticosteroids, immunomodulators, ultra violet light therapy or other medication (investigational or otherwise) that may have an effect on atopic dermatitis disease progression for 30 days prior to the baseline measurement.

• Subjects on a stable maintenance therapy (at least 30 days of use prior to baseline) of antihistamines and/or nasal spray containing corticosteroids for the treatment of bronchial asthma or allergic rhinitis, and antibiotics for the treatment of acne will be allowed.

• Subjects who are willing to discontinue use of topical treatments for AD including, but not limited to, corticosteroids, immunomodulators, vitamin D treatments, retinoids, topical antihistamines for at least 14 days prior to baseline

• Subjects who are willing to discontinue use of oral antibiotic therapy for at least 7 days prior to baseline, unless prescribed for acne treatment as previously described

• Subjects with no known allergy to any of the study product ingredients

• Women of childbearing potential must be willing to use a form of birth control during the study. For the purpose of this study, the following are considered acceptable methods of birth control: oral contraceptives, Norplant, Depo-Provera, double barrier methods (e.g., condom and spermicide) and abstinence.

Exclusion Criteria:

• immunocompromised patients, or subjects with extensive disease that could not reasonably be controlled with topical therapy

• history or evidence of other conditions that would interfere with the evaluation of the study medication

• subjects desiring excessive or prolonged exposure to UV light (e.g. sunlight/tanning beds) during the study

• Use of topical medications for AD or any other medical condition.

• Subjects currently involved in another clinical research study.

• Subjects, who are pregnant, breast feeding or planning a pregnancy.

• Subjects with clinically significant unstable medical or mental disorders.

• Subjects who are unwilling or unable to comply with the requirements of the protocol.

Related Conditions & MeSH terms

• Atopic Dermatitis
• Dermatitis
• Dermatitis, Atopic
• Eczema

Intervention

Drug:
• Locoid Lipocream
Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
• Hylatopic Plus
Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.

Locations

Country	Name	City	State
United States	Icahn School of Medicine at Mount Sinai	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Icahn School of Medicine at Mount Sinai

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline Treatment Success at Day 29	Treatment Success defined as Clear or Almost Clear (0 or 1) on the 5 point static physician global assessment of psoriasis (SPGA) scale at day 29, evaluating non-inferiority of one group compared to the other using the lower limit of the confidence interval for the difference in success proportions, as compared to baseline.	baseline and Day 29
Secondary	Change from Baseline SPGA scale at Day 29	2 point reduction of SPGA at day 29 as compared to baseline. The sPGA is a physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA of psoriasis comprises a 6-point scale ranging from 0 (clear) to 5 with increasing severity.	baseline and Day 29
Secondary	Change from Baseline Pruritus at Day 29	Change from baseline pruritus at day 29	baseline and Day 29